TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Acquires $22,750.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom acquired 5,000 shares of the business’s stock in a transaction dated Friday, November 22nd. The stock was acquired at an average cost of $4.55 per share, with a total value of $22,750.00. Following the purchase, the director now directly owns 15,727 shares in the company, valued at $71,557.85. This represents a 46.61 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Mats Wahlstrom also recently made the following trade(s):

• On Wednesday, November 20th, Mats Wahlstrom purchased 2,040 shares of TriSalus Life Sciences stock. The shares were bought at an average price of $4.16 per share, with a total value of $8,486.40.

TriSalus Life Sciences Price Performance

TLSI traded down $0.30 on Monday, hitting $4.23. The company had a trading volume of 65,496 shares, compared to its average volume of 38,543. TriSalus Life Sciences, Inc. has a 1-year low of $3.61 and a 1-year high of $10.42. The company’s fifty day moving average price is $4.25 and its 200 day moving average price is $5.56. The stock has a market cap of $128.99 million, a price-to-earnings ratio of -1.68 and a beta of 0.49.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Highbridge Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences in the second quarter valued at approximately $1,184,000. Duquesne Family Office LLC increased its position in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after buying an additional 110,966 shares during the period. Geode Capital Management LLC increased its stake in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares in the last quarter. Wolverine Asset Management LLC bought a new stake in TriSalus Life Sciences during the 2nd quarter valued at $240,000. Finally, MSD Partners L.P. purchased a new stake in TriSalus Life Sciences in the 3rd quarter valued at $184,000. 2.58% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TLSI has been the subject of several recent research reports. Roth Mkm began coverage on TriSalus Life Sciences in a research report on Monday, November 11th. They issued a “buy” rating and a $11.00 price target for the company. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Canaccord Genuity Group cut their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target on the stock. Finally, Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $12.08.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.